Roy Buchanan
Stock Analyst at JMP Securities
(4.00)
# 494
Out of 5,182 analysts
46
Total ratings
56.86%
Success rate
126.74%
Average return
Main Sectors:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASMB Assembly Biosciences | Initiates: Market Outperform | $38 | $27.87 | +36.35% | 1 | Sep 24, 2025 | |
| ENTA Enanta Pharmaceuticals | Maintains: Market Outperform | $24 → $25 | $13.31 | +87.83% | 15 | Aug 12, 2025 | |
| PYPD PolyPid | Maintains: Market Outperform | $16 → $14 | $4.62 | +203.03% | 2 | Jun 17, 2025 | |
| ANTX AN2 Therapeutics | Maintains: Market Outperform | $5 → $2 | $4.36 | -54.13% | 9 | May 5, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $1.15 | +1,465.22% | 3 | Mar 14, 2025 | |
| TPG TPG Inc. | Reiterates: Market Perform | n/a | $43.62 | - | 1 | Feb 13, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $7 → $4 | $1.91 | +109.42% | 3 | Feb 11, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Outperform | $23 → $14 | $3.93 | +256.23% | 1 | Jan 30, 2025 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Market Outperform | $33 | $114.56 | -71.19% | 1 | Jan 10, 2025 | |
| ABUS Arbutus Biopharma | Maintains: Market Outperform | $4 → $5 | $4.20 | +19.05% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $443 → $448 | $780.25 | -42.58% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $7.42 | +115.63% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.68 | - | 2 | Feb 16, 2023 |
Assembly Biosciences
Sep 24, 2025
Initiates: Market Outperform
Price Target: $38
Current: $27.87
Upside: +36.35%
Enanta Pharmaceuticals
Aug 12, 2025
Maintains: Market Outperform
Price Target: $24 → $25
Current: $13.31
Upside: +87.83%
PolyPid
Jun 17, 2025
Maintains: Market Outperform
Price Target: $16 → $14
Current: $4.62
Upside: +203.03%
AN2 Therapeutics
May 5, 2025
Maintains: Market Outperform
Price Target: $5 → $2
Current: $4.36
Upside: -54.13%
Inovio Pharmaceuticals
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $1.15
Upside: +1,465.22%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $43.62
Upside: -
Esperion Therapeutics
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $1.91
Upside: +109.42%
Ironwood Pharmaceuticals
Jan 30, 2025
Maintains: Market Outperform
Price Target: $23 → $14
Current: $3.93
Upside: +256.23%
ABIVAX Société Anonyme
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $114.56
Upside: -71.19%
Arbutus Biopharma
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $4.20
Upside: +19.05%
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $780.25
Upside: -42.58%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $7.42
Upside: +115.63%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.68
Upside: -